The biomimetic platform was designed for site-specific and sequential delivery of two anticancer agents: TNF-related apoptosis-inducing ligand (TRAIL), known to induce cancer cell apoptosis by selectively interacting with the surface death receptors (DR4, DR5) [211], and DOX (TRAIL-Dox-PM-NV) [216] (Figure 1). Here, TNFSF10 is linked to cancer.